Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
Complete Omics published novel technologies on SCIENCE and SCIENCE IMMUNOLOGY.
To identify truly personalized cancer therapeutic target is the 1st step of the personalized cancer therapeutics. Complete Omics’ Multi-Omics molecular diagnostic pipeline has achieved two extraordinary achievements in this new incoming era, and we are dedicated to develop more advanced multi-omics molecular diagnostic technologies and will focus on taking them to rapid commercialization.
Congratulations to our lab alumni founders in Thrive Earlier Detection.
NEW YORK – Exact Sciences has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection for cash and stock consideration of up to $2.15 billion.
MANA-SRM pipeline and its application in personalized cancer therapeutics.
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
SAFE-SRM, 1st pipeline for clinical proteomics
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
MT-SRM, direct detection of mutant proteins as cancer-specific biomarkers
SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.
